| Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies TA Yap, D Olmos, AT Brunetto, N Tunariu, J Barriuso, R Riisnaes, L Pope, ... Journal of Clinical Oncology 29 (10), 1271-1279, 2011 | 222 | 2011 |
| Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies D Olmos, D Barker, R Sharma, AT Brunetto, TA Yap, AB Taegtmeyer, ... Clinical cancer research 17 (10), 3420-3430, 2011 | 187 | 2011 |
| Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review LV dos Santos, FH Souza, AT Brunetto, AD Sasse, ... Journal of the National Cancer Institute 104 (17), 1280-1292, 2012 | 146 | 2012 |
| Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors D Olmos, RP A'hern, S Marsoni, R Morales, C Gomez-Roca, J Verweij, ... Journal of Clinical Oncology 30 (9), 996-1004, 2012 | 81 | 2012 |
| A phase I study of MK-2206, an oral potent allosteric Akt inhibitor (Akti), in patients (pts) with advanced solid tumor (ST) AW Tolcher, TA Yap, I Fearen, A Taylor, C Carpenter, AT Brunetto, ... Journal of Clinical Oncology 27 (15_suppl), 3503-3503, 2009 | 79 | 2009 |
| First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors AT Brunetto, JE Ang, R Lal, D Olmos, LR Molife, R Kristeleit, A Parker, ... Clinical Cancer Research 19 (19), 5494-5504, 2013 | 67 | 2013 |
| Gastrin-releasing peptide receptor expression in lung cancer J Mattei, RD Achcar, CH Cano, BR Macedo, L Meurer, BS Batlle, ... Archives of Pathology and Laboratory Medicine 138 (1), 98-104, 2014 | 60 | 2014 |
| Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity C Messiou, M Orton, JE Ang, DJ Collins, VA Morgan, D Mears, ... Radiology 265 (2), 426-436, 2012 | 55 | 2012 |
| The use of high‐frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin‐based chemotherapy AL Abujamra, JR Escosteguy, C Dall'Igna, D Manica, LF Cigana, ... Pediatric blood & cancer 60 (3), 474-478, 2013 | 49 | 2013 |
| Current and emerging molecular targets in glioma R Roesler, AT Brunetto, AL Abujamra, CB de Farias, AL Brunetto, ... Expert Review of Anticancer Therapy 10 (11), 1735-1751, 2010 | 45 | 2010 |
| Trk inhibition reduces cell proliferation and potentiates the effects of chemotherapeutic agents in Ewing sarcoma TE Heinen, RP Dos Santos, A da Rocha, MP Dos Santos, ... Oncotarget 7 (23), 34860, 2016 | 43 | 2016 |
| Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer CR Petrarca, AT Brunetto, V Duval, A Brondani, GP Carvalho, ... Clinical Breast Cancer 11 (2), 129-134, 2011 | 42 | 2011 |
| Targeting histone deacetylase activity to arrest cell growth and promote neural differentiation in Ewing sarcoma BK Souza, PL da Costa Lopez, PR Menegotto, IA Vieira, N Kersting, ... Molecular neurobiology 55, 7242-7258, 2018 | 38 | 2018 |
| Histone deacetylase inhibitors in pediatric brain cancers: biological activities and therapeutic potential A Perla, L Fratini, PS Cardoso, C Nör, AT Brunetto, AL Brunetto, ... Frontiers in Cell and Developmental Biology 8, 546, 2020 | 34 | 2020 |
| Phase I study of olaparib in combination with carboplatin and/or paclitaxel in patients with advanced solid tumors. R van der Noll, JE Ang, A Jager, S Marchetti, M Mergui-Roelvink, ... Journal of clinical oncology 31 (15_suppl), 2579-2579, 2013 | 31 | 2013 |
| Combined treatments with a retinoid receptor agonist and epigenetic modulators in human neuroblastoma cells VR Almeida, IA Vieira, M Buendia, AT Brunetto, LJ Gregianin, AL Brunetto, ... Molecular Neurobiology 54, 7610-7619, 2017 | 27 | 2017 |
| A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumors LR Molife, EJ Dean, M Blanco-Codesido, MG Krebs, AT Brunetto, ... Clinical Cancer Research 20 (24), 6284-6294, 2014 | 27 | 2014 |
| HDAC and MAPK/ERK inhibitors cooperate to reduce viability and stemness in medulloblastoma M da Cunha Jaeger, EC Ghisleni, PS Cardoso, M Siniglaglia, T Falcon, ... Journal of Molecular Neuroscience 70, 981-992, 2020 | 25 | 2020 |
| Neurotrophin signaling in medulloblastoma A Thomaz, M Jaeger, AL Brunetto, AT Brunetto, L Gregianin, CB de Farias, ... Cancers 12 (9), 2542, 2020 | 24 | 2020 |
| Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet … AT Brunetto, CP Carden, J Myerson, AL Faria, S Ashley, S Popat, ... Journal of Thoracic Oncology 5 (9), 1397-1403, 2010 | 23 | 2010 |
